transforming-growth-factor-beta and Cardiovirus-Infections

transforming-growth-factor-beta has been researched along with Cardiovirus-Infections* in 3 studies

Other Studies

3 other study(ies) available for transforming-growth-factor-beta and Cardiovirus-Infections

ArticleYear
Seizures following picornavirus infection.
    Epilepsia, 2008, Volume: 49, Issue:6

    We demonstrate the establishment and characterization of a novel virus infection-induced seizure model in C57BL/6 mice.. C57BL/6 mice were infected with Theiler's murine encephalomyelitis virus (TMEV) or mock infected. Mice were followed for seizures, weight change, body temperature, motor function (righting reflex, rotorod) and neurological manifestations (inflammation [perivascular cuffing], pyknotic neurons, transforming growth factor [TGF]-beta expression).. C57BL/6 mice are susceptible to seizures induced by TMEV infection. Approximately 50% of C57BL/6 mice develop transient afebrile seizures. Motor function and coordination are impaired in seized mice. Pyramidal neuron pyknosis and TGF-beta expression correlate with seizure activity in the hippocampus.. The characterization of this model will enable the investigation of viral and immune contributions in the central nervous system to the development of seizure disorders in humans.

    Topics: Animals; Brain; Cardiovirus Infections; Epilepsy, Tonic-Clonic; Female; Hippocampus; Immunoenzyme Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Motor Skills; Neurons; Postural Balance; Reflex; Seizures; Theilovirus; Transforming Growth Factor beta

2008
TGF-beta 2 reduces demyelination, virus antigen expression, and macrophage recruitment in a viral model of multiple sclerosis.
    Journal of immunology (Baltimore, Md. : 1950), 2000, Mar-15, Volume: 164, Issue:6

    TGF-beta 2 is a potent immunoregulatory mediator that influences B cell, T cell, and macrophage function. To test whether this cytokine alters pathology in a model of virus-induced demyelinating disease, we treated SJL/J mice with TGF-beta 2 either before or after infection with Theiler's murine encephalomyelitis virus. Treatment continued three times weekly through day 35 postinfection. TGF-beta 2 administration resulted in significantly smaller lesions and fewer virus Ag-positive cells in the spinal cords of infected SJL/J mice. Mice treated with TGF-beta 2 had similar levels of virus-specific IgG as infected, control-treated mice. TGF-beta 2 administration significantly increased the level of non-virus-specific activated CTLs, but had no effect on virus-specific CTLs. TUNEL revealed a decrease in the number of apoptotic nuclei in the spinal cord white matter of mice treated in vivo with TGF-beta 2. Immunostaining with an Ab to F4/80 revealed that TGF-beta 2-treated mice had significantly fewer F4/80-positive cells in the white matter of the spinal cord as compared with infected control-treated mice. These data suggest that TGF-beta 2 may control virus-induced demyelination via an immunomodulatory mechanism that reduces macrophage infiltration.

    Topics: Animals; Antigens, Viral; Apoptosis; Cardiovirus Infections; Cell Count; Cytotoxicity Tests, Immunologic; Disease Models, Animal; Disease Susceptibility; Female; Injections, Intraperitoneal; Macrophages; Mice; Mice, Inbred Strains; Multiple Sclerosis; Myelin Sheath; Spinal Cord; T-Lymphocytes, Cytotoxic; Theilovirus; Transforming Growth Factor beta; Viral Plaque Assay; Virus Replication

2000
Differential expression of TGF-beta, IL-2, and other cytokines in the CNS of Theiler's murine encephalomyelitis virus-infected susceptible and resistant strains of mice.
    Virology, 2000, Dec-20, Volume: 278, Issue:2

    Intracranial inoculation of susceptible SJL mice with Theiler's murine encephalomyelitis virus (TMEV) results in biphasic disease consisting of early acute disease, followed by late chronic demyelinating disease, associated with mononuclear infiltrates and demyelinating lesions. In contrast, resistant C57BL/6 (B6) mice develop only early acute disease. We employed cytokine-specific RT-PCR to determine the expression of cytokine transcripts in the CNS of TMEV-infected SJL and B6 mice. During early acute disease, we have found a strong proinflammatory (Th1) cytokine response in the CNS of both TMEV-infected SJL and B6 mice, demonstrated by the expression of transcripts for IFN-gamma, IL-1, IL-6, IL-12p40, and TNF-alpha. At 8 days postinfection (p.i.), TGF-beta1 and TNF-alpha transcripts were present at significantly higher levels (P < 0.01) in the CNS of SJL susceptible mice in comparison to those found in the CNS of B6 mice. Immunohistochemical staining revealed that TGF-beta protein was expressed in leptomeningeal mononuclear inflammatory cell infiltrates in the brain of SJL mice but not in B6 mice, at 8 days p.i. TGF-beta may be responsible for the failure of SJL mice to develop an effective anti-TMEV CTL response. During late chronic demyelinating disease, high levels of proinflammatory Th1 cytokines were found in the CNS of SJL mice, but not B6 mice. Significantly higher levels (P < 0.01) of anti-inflammatory cytokine transcripts (IL-4, IL-5, and IL-10 (Th2 cytokines) and TGF-beta) were found in the spinal cord of TMEV-infected SJL mice with chronic demyelinating disease than in the spinal cord of B6 mice during the same time period (39 or 60 days p.i.). These anti-inflammatory cytokines may contribute to the downregulation of the proinflammatory response in SJL mice. High levels of IL-2 transcripts and protein appeared transiently in the spinal cord of TMEV-infected SJL mice before the onset of demyelinating disease and coincided with an influx of new T cells into the CNS and/or expansion of remaining T cells that have not been eliminated after viral clearance.

    Topics: Animals; Brain; Cardiovirus Infections; Cytokines; Disease Susceptibility; Gene Expression Regulation; Immunity, Innate; Inflammation; Interleukin-2; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Species Specificity; Spinal Cord; Th1 Cells; Theilovirus; Time Factors; Transcription, Genetic; Transforming Growth Factor beta

2000